Icon (ICLR) to Release Earnings on Wednesday

Key Points

• Icon (ICLR) is set to release its Q3 2025 earnings on October 22nd, with analysts predicting earnings of $3.28 per share and revenue of $1.9848 billion.
• In its last earnings report, Icon reported $3.26 EPS, exceeding expectations, but its revenue declined 4.8% year-over-year.
• Analysts have differing outlooks on Icon, with a consensus rating of "Moderate Buy" and a target price of $210.64, reflecting cautious optimism about the company's performance.

Icon (NASDAQ:ICLR - Get Free Report) is expected to post its Q3 2025 results after the market closes on Wednesday, October 22nd. Analysts expect Icon to post earnings of $3.28 per share and revenue of $1.9848 billion for the quarter. Icon has set its FY 2025 guidance at 13.000-14.000 EPS.Individuals may visit the the company's upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Thursday, October 23, 2025 at 8:00 AM ET.

Icon (NASDAQ:ICLR - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $3.26 earnings per share for the quarter, beating analysts' consensus estimates of $3.18 by $0.08. Icon had a return on equity of 10.95% and a net margin of 9.82%.The company had revenue of $2.02 billion during the quarter, compared to analyst estimates of $1.98 billion. During the same quarter last year, the company earned $3.75 EPS. The firm's revenue for the quarter was down 4.8% on a year-over-year basis. On average, analysts expect Icon to post $13 EPS for the current fiscal year and $15 EPS for the next fiscal year.

Icon Stock Down 0.1%

ICLR stock opened at $185.91 on Wednesday. Icon has a twelve month low of $125.10 and a twelve month high of $301.45. The company has a quick ratio of 1.29, a current ratio of 1.29 and a debt-to-equity ratio of 0.35. The firm has a market cap of $15.01 billion, a PE ratio of 19.13, a price-to-earnings-growth ratio of 2.76 and a beta of 1.23. The business has a 50 day moving average of $175.39 and a 200 day moving average of $156.96.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Citigroup reaffirmed a "neutral" rating and set a $200.00 price objective (down previously from $225.00) on shares of Icon in a research report on Thursday, August 21st. Mizuho raised their price objective on Icon from $173.00 to $225.00 and gave the company an "outperform" rating in a research report on Friday, July 25th. Cowen reaffirmed a "hold" rating on shares of Icon in a research report on Friday, September 12th. Jefferies Financial Group lowered Icon from a "buy" rating to a "hold" rating and reduced their price objective for the company from $220.00 to $175.00 in a research report on Tuesday, September 9th. Finally, Weiss Ratings reiterated a "hold (c)" rating on shares of Icon in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $210.64.

Institutional Trading of Icon

Institutional investors have recently added to or reduced their stakes in the business. Geneos Wealth Management Inc. boosted its stake in Icon by 11.5% during the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company's stock valued at $79,000 after purchasing an additional 56 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Icon by 58.7% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 781 shares of the medical research company's stock worth $113,000 after buying an additional 289 shares during the last quarter. Peapack Gladstone Financial Corp purchased a new position in shares of Icon in the 2nd quarter worth $212,000. WINTON GROUP Ltd purchased a new position in shares of Icon in the 2nd quarter worth $254,000. Finally, White Knight Strategic Wealth Advisors LLC purchased a new position in shares of Icon in the 2nd quarter worth $262,000. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

About Icon

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.